Jay R. Luly, President and CEO at ENANTA PHARMACEUTICALS INC (ENTA), sold 15,000 shares at $44.99 ($681K) on 2014-12-01, disclosed to the SEC on 2014-12-02.
Scheduled sale ($681k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.99 | 11,400 | $513K | 75.3% |
| 2 | $45.96 | 1,200 | $55K | 8.1% |
| 3 | $46.97 | 2,400 | $113K | 16.6% |
| Total | $45.38 avg | 15,000 | $681K | 100% |
| Filing → |
| ENTA | SELL | 2024-12-10 | $41K | — | Filing → |
| ENTA | SELL | 2023-12-06 | $139K | — | Filing → |
| ENTA | SELL | 2023-03-14 | $2.5M | — | Filing → |